India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
The Russian Ministry of Health has registered the third Russian generic of the original drug Ozempic (semaglutide) from Danish drugmaker Novo Nordisk. 8 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024
In 2023, more than 50% (28 of 55) of the novel drugs reviewed by the US Food and Drug Administration (FDA) received orphan drug designation for the prevention, diagnosis, or treatment of a rare disease.1 20 February 2024
Leading Russian patient associations have called on the state to expand the list of vital drugs and increase their procurements this year, reports The Pharma Letter’s local correspondent. 16 February 2024
Russia plans to consider issuing a compulsory license for dolutegravir, one of Russia’s most demanded anti-HIV drugs, reports The Pharma Letter’s local correspondent. 15 February 2024
India has achieved a notable milestone in the field of cancer treatment with its indigenously developed CAR-T cell therapy, resulting in the first patient being declared cancer-free post treatment. 15 February 2024
The share of cheap drugs in the Russian pharmaceutical market is steadily declining, while in the last three years their overall range in the market has declined two-fold, reports The Pharma Letter’s local correspondent. 7 February 2024
The Russian drugmaker Axelpharm is demanding a compulsory license for an antitumor drug based on Bosulif (bosutinib), marketed by US pharma giant Pfizer, reports The Pharma Letter’s local correspondent. 6 February 2024
Drugmakers from China and India have been unable to replace clinical trials on original drugs from Western manufacturers on the Russian market after February, 24 2022, The Pharma Letter’s local correspondent reports. 29 January 2024
Russia has faced a shortage of another important anticancer drug - Ixempra (ixabepilone), which is designed for the treatment of breast cahttps://mail.google.com/mail/cancer, reports The Pharma Letter’s local correspondent. 27 January 2024
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine condition that develops in the parafollicular C cells of the thyroid gland.1 It makes up 3%-5% of all thyroid cancers, with a 10-year mortality rate of about 50%.2 20 January 2024
While 2023 saw the approval of many notable new drugs by the US Food and Drug Administration (FDA), the past year also featured many holds being imposed on clinical trials. 18 January 2024
Vyacheslav Kokeladze, a well-known Russian businessman and pharmaceutical tycoon, is investing about 1.4 billion roubles ($20 million) in the establishment of one of the country’s largest production facilities for generic medicines. 16 January 2024
Russia plans to revise the main concepts of public procurements of anti-tuberculosis drugs in a move to switch on the purchases of more efficient drugs with lower cost and side effects, The Pharma Letter’s local correspondent reports. 15 January 2024
The Indian diabetes battleground is experiencing a fresh wave of firepower, with both domestic and multinational pharma giants unleashing a barrage of new anti-diabetic drugs, The Pharma Letter's local correspondent reports. 15 January 2024
Russia may be faced with a shortage of some important antibiotics next year due to the recent decision of some global drugmakers to withdraw them from the market, The Pharma Letter’s local correspondent reports. 29 December 2023
India's aspiration for pharmaceutical self-reliance hit a rough patch as recent data indicates a surge in imports of bulk drugs and intermediates from various countries, including China, over the past two years. 28 December 2023
The level of competition in the Russian pharmaceutical market will significantly tighten next year, as local drugmakers plan to overtake global producers in the segment of public procurements, reports The Pharma Letter’s local correspondent. 28 December 2023
Japan’s innovative pharma market has been on an upwards trajectory these last 12 months – despite what you may have seen in IQVIA thought leadership reports, industry advocacy body pronouncements or USD-reported results. 27 December 2023
Foreign contract research companies (CROs) are suspending participating in clinical trials in Russia after the exodus of global drugmakers from the clinical research market in the country earlier this year, reports The Pharma Letter’s local correspondent. 20 December 2023
Amid the ever-declining drug imports from Western countries, Russia is ready to increase supplies of drugs from so-called “friendly” countries, The Pharma Letter’s local correspondent report. 19 December 2023